General Updates

Date: September 28, 2026 Ref. No.: KDL/SE/049/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA Dear Sir/Madam, Subject: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Krsnaa Diagnostics Limited (“Company”), at its meeting held today, has approved the sale of identified diagnostic equipment for an aggregate consideration of up to ₹120 crore to identified purchaser(s), including purchaser(s) that may be identified in the future. The proposed transaction forms part of the Company’s ongoing strategic initiative to optimise its asset portfolio and enhance capital efficiency. Over the years, the Company has established a significant asset base to support the expansion of its diagnostic operations. As the Company progresses towards an increasingly asset-light and capital-efficient operating model, it has identified certain assets that can be monetised without impacting its core operating capabilities. The proposed sale is intended to unlock value from such identified assets and facilitate efficient recycling of capital towards the Company’s core diagnostic business and identified growth opportunities. The initiative is expected to support improved asset utilisation, enhance return on capital employed (ROCE) and strengthen the Company’s balance sheet, while enabling the Company to remain focused on scalable and sustainable growth. The assets proposed to be sold comprise identified freehold assets which are not subject to any security interest created in favour of the Company’s lenders and, accordingly, the proposed transaction will not impact the assets forming part of the security package provided to the lenders. The proposed transaction is an exercise in active portfolio and capital optimisation and is not driven by any impairment or diminution in the value of the underlying assets. The transaction is not expected to have any material adverse impact on the Company’s profit and loss account or its ongoing business operations. Further, the proposed transaction does not constitute a sale, lease or disposal of an undertaking or substantially the whole of the undertaking of the Company within the meaning of Section 180(1)(a) of the Companies Act, 2013. The Board has authorised the Operations Committee to finalise the terms and conditions of the transaction and undertake all necessary formalities in connection therewith, within the aggregate limit approved as aforesaid. The meeting commenced at 14:00 hrs (IST) and concluded at 18:30 hrs (IST). You are requested to take the above information on record For Krsnaa Diagnostics Limited Sujoy Sudipta Bose Company Secretary and Compliance Officer